PDP

ONCOSEM ONKOLOJİK SİSTEMLER SANAYİ VE TİCARET A.Ş.

ONCSM

Publish Date

10.04.202618:11:27

Disclosure Type

ÖDA

Year

Period

Notification Attachments (0)

No Attachment!

Related Party Transactions

Notification Attachments (0)

No Attachment!

Notifications Financial Statements Corporate Actions

PDF

WORD

EXCEl

At the meeting of our Board of Directors held on April 8, 2026;

Within the scope of Article 10 of the Corporate Governance Communiqué (II-17.1) ("Communiqué") of the Capital Markets Board ("CMB"), in the event that the amount of common and continuous transactions between companies whose shares are traded on Borsa İstanbul and their subsidiaries and related parties within an accounting period is expected to exceed 10%:

In terms of purchase transactions, of the ratio to the cost of sales based on the latest publicly disclosed annual financial statements,
In terms of sales transactions, of the ratio to the revenue amount based on the latest publicly disclosed annual financial statements,

it is stipulated that a report regarding the terms of such transactions and their comparison with market conditions shall be prepared by the Board of Directors, and that the full report or its conclusion shall be disclosed on the Public Disclosure Platform ("PDP").

In this context, it has been unanimously resolved by the members attending the meeting to approve the "Report on Common and Continuous Related Party Transactions" prepared regarding the transactions between our Company and our subsidiary, Santek Sağlık Turizm Tekstil ve Sanayi A.Ş.

The conclusion section of the report is provided belo

"Pursuant to Article 10 of the Corporate Governance Communiqué (II-17.1) of the Capital Markets Board, the ratio of the amount of common and continuous transactions between our Company and Santek Sağlık Turizm Tekstil ve Sanayi A.Ş. within an accounting period to the annual revenue amount is expected to exceed the 10% threshold for sales transactions. In this Report, information is provided on the compliance of such transactions with market conditions by explaining the terms, pricing method, and the rationale for the selection of such method regarding the transactions carried out with Santek Sağlık Turizm Tekstil ve Sanayi A.Ş. in 2025 and those expected to continue under similar conditions in 2026."

Respectfully announced to the public.

The English translation of this disclosure is provided in the annex, and in the event of any discrepancy between the texts, the Turkish version shall prevail.